Cystic fibrosis (paediatric)
respiratory · Paediatric
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Autosomal recessive CFTR disorder causing thick secretions, chronic suppurative lung disease, pancreatic insufficiency and salt loss. Most are detected by newborn screening; management is lifelong, multidisciplinary, and increasingly includes CFTR modulators.
Red flags
- New Pseudomonas aeruginosa isolation (needs eradication therapy)
- Haemoptysis or pneumothorax
- Distal intestinal obstruction syndrome (DIOS)
- Rapid lung function decline or faltering growth
Assessment
Differential diagnosis
- Recurrent/chronic chest infection from other cause
- Primary ciliary dyskinesia
- Immunodeficiency
- Coeliac disease (malabsorption/faltering growth)
- Asthma with recurrent infection
- Protracted bacterial bronchitis
- Shwachman-Diamond syndrome
Investigations
- Newborn blood spot (immunoreactive trypsinogen) then CFTR genetic testing
- Sweat chloride test (diagnostic: elevated chloride)
- Extended CFTR gene panel/sequencing
- Faecal elastase (low in pancreatic insufficiency)
- Respiratory cultures/cough swabs for Pseudomonas, Staph aureus, etc.
- Baseline and serial spirometry, chest imaging, glucose tolerance and bone/liver surveillance
Management
- Confirm diagnosis with sweat test and genotype after positive screening
- Refer to a specialist CF multidisciplinary centre promptly
- Start airway clearance physiotherapy and mucoactive agents
- Begin pancreatic enzyme replacement and fat-soluble vitamin supplementation if insufficient
- Optimise high-energy, high-salt nutrition and monitor growth closely
- Treat respiratory infections aggressively and provide antibiotic prophylaxis per protocol
- Commence CFTR modulator therapy where genotype-eligible
- Monitor for complications (CF-related diabetes, liver disease, bone disease)
- Ensure vaccinations, segregation to prevent cross-infection, and psychosocial support
Drugs & doses
Pancreatic enzyme replacement (Creon) ~2000-4000 units lipase per gram of dietary fat, titrated to stools/growth
Fat-soluble vitamins (A, D, E, K) daily supplementation
Dornase alfa 2.5 mg nebulised once daily (mucolytic)
Flucloxacillin prophylaxis ~12.5-25 mg/kg twice daily in young children; CFTR modulators (e.g. elexacaftor/tezacaftor/ivacaftor) for eligible genotypes
Disposition
Lifelong specialist CF centre care with shared-care; admit for exacerbations, DIOS, or acute deterioration.
Complications & pitfalls
- Bronchiectasis and progressive respiratory failure
- Pancreatic insufficiency, CF-related diabetes and liver disease
- Distal intestinal obstruction syndrome and rectal prolapse
- Osteoporosis, male infertility and salt-depletion crises
Exam pearls
- Early Pseudomonas should be aggressively eradicated to delay chronic colonisation
- Adequate enzyme dosing and high-calorie nutrition are central to outcome
- CFTR modulators have transformed prognosis for eligible genotypes
- Strict cross-infection control between CF patients is essential
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.